(thirdQuint)Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus.

 This is a randomized, double-blind, placebo-controlled, parallel group, multiple dose, multicenter study with 5 treatment arms and 1 placebo arm.

 Patients should be treated with both metformin and SU or metformin alone.

 Patients will be randomized to 100,100 + 100, 200, 200 + 200, and 400 mg/day or placebo, as an add-on to their current treatment.

 The study consists of 2 periods: - A 14-day screening period for ascertaining the inclusion/exclusion criteria; and, - A 13-week treatment period with different doses of BGP-15 or placebo as an add-on therapy to metformin and SU treatment or metformin treatment alone.

.

 Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus@highlight

This is a safety and dose finding efficacy study to evaluate the effects of BGP-15 over the dose range of 100 mg/day to 400 mg/day.

 Doses are applied once or twice a day for 13 weeks as add-on therapy to the combination of metformin and sulfonylurea treatment or metformin alone in patients with Type 2 Diabetes Mellitus.

